The antigen-presenting cell (APC) plays a key role in the initiation and regulation of immune responses. First, the APC processes and presents antigens in a way that they can be recognized by T lymphocytes. Second, it synthesizes costimulatory molecules that are crucial for the activation of T lymphocytes. Triggering of the T cell receptor in the absence of a costimulatory signal is not sufficient to induce complete T cell activation. In contrast, it can lead to T cell anergy. Furthermore, costimulatory ligands may be involved in selection processes in the thymus. It has been suggested that the B7 antigen functions as the major costimulatory ligand in the activation of interleukin-2 secreting CD4+ T lymphocytes. We have developed reagents that allow us to test this hypothesis and to characterize the precise role of the murine B7 (mB7) molecule in the activation and development of murine CD4+ T lymphocytes. We have expressed the mB7 cDNA in chinese hamster ovary cells and have shown that the resulting cell line is capable of costimulating T cell activation. We have also developed a hamster-anti mB7 monoclonal antibody that is capable of blocking costimulation by mB7. Finally, we are in the process of producing a soluble recombinant form of mB7. Using these reagents we plan in this proposal: (i) to study the expression of mB7 by different APC's and how it is regulated, to study the function of mB7 on different APCs, and to determine which T cell populations respond to mB7 triggering; (ii) to determine whether mB7 plays a role in the prevention/maintenance of T cell anergy and whether it is required for immune responses in vivo; (iii) to analyze whether mB7 plays a role in thymic development. We anticipate that our studies will provide important insights into the biology of the immune system. Furthermore, studies on the biologic role of mB7 may provide the basis for further clinical investigations. A pharmacological reagent that interferes with triggering of the costimulatory pathway, e.g. an altered ligand (B7), has the potential to induce T cell tolerance and may be useful in the prevention of allograft rejection. It is also conceivable that a recombinant form of B7 may be useful in situations where it is desirable to upregulate immune functions, for example in the generation of vaccines.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI033679-02
Application #
2068727
Study Section
Immunobiology Study Section (IMB)
Project Start
1993-01-01
Project End
1995-12-31
Budget Start
1994-01-01
Budget End
1994-12-31
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Razi-Wolf, Z; Hollander, G A; Reiser, H (1996) Activation of CD4+ T lymphocytes form interleukin 2-deficient mice by costimulatory B7 molecules. Proc Natl Acad Sci U S A 93:2903-8
Reiser, H; Stadecker, M J (1996) Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335:1369-77
Reiser, H; Schneeberger, E E (1996) Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity. Eur J Immunol 26:880-5
Wetzler, L M; Ho, Y; Reiser, H et al. (1996) Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate. J Exp Med 183:1151-9
Natesan, M; Razi-Wolf, Z; Reiser, H (1996) Costimulation of IL-4 production by murine B7-1 and B7-2 molecules. J Immunol 156:2783-91
Flores Villanueva, P O; Reiser, H; Stadecker, M J (1994) Regulation of T helper cell responses in experimental murine schistosomiasis by IL-10. Effect on expression of B7 and B7-2 costimulatory molecules by macrophages. J Immunol 153:5190-9
Reiser, H; Schneeberger, E E (1994) The costimulatory molecule B7 is expressed in the medullary region of the murine thymus. Immunology 81:532-7
Razi-Wolf, Z; Falo Jr, L D; Reiser, H (1994) Expression and function of the costimulatory molecule B7 on murine Langerhans cells: evidence for an alternative CTLA-4 ligand. Eur J Immunol 24:805-11
Razi-Wolf, Z; Galvin, F; Gray, G et al. (1993) Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor. Proc Natl Acad Sci U S A 90:11182-6
Freeman, G J; Borriello, F; Hodes, R J et al. (1993) Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 178:2185-92